Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
20.55
+0.39 (1.93%)
Mar 6, 2026, 10:39 AM EST - Market open
Apollomics Employees
Apollomics had 13 employees as of December 31, 2024. The number of employees decreased by 32 or -71.11% compared to the previous year.
Employees
13
Change (1Y)
-32
Growth (1Y)
-71.11%
Revenue / Employee
$533,077
Profits / Employee
-$2,399,077
Market Cap
44.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -32 | -71.11% |
| Dec 31, 2023 | 45 | 2 | 4.65% |
| Dec 31, 2022 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| NextCure | 43 |
| Palatin Technologies | 29 |
| Veru Inc. | 20 |
| Lipocine | 16 |
| Atossa Therapeutics | 15 |
| Telomir Pharmaceuticals | 9 |
| Lite Strategy | 4 |
APLM News
- 2 months ago - Apollomics Reports First Half 2025 Financial Results - GlobeNewsWire
- 3 months ago - Apollomics Announces Settlement of Cayman Litigation - GlobeNewsWire
- 3 months ago - Apollomics Announces Changes to its Board of Directors and Composition of Committees - GlobeNewsWire
- 5 months ago - Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - GlobeNewsWire
- 5 months ago - Apollomics, Inc. Company Operational Continuity Update - GlobeNewsWire
- 1 year ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire
- 1 year ago - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewsWire
- 1 year ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire